49
Participants
Start Date
August 9, 2021
Primary Completion Date
July 24, 2024
Study Completion Date
July 24, 2024
pepinemab + pembrolizumab
The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
Northwell Health - Centers for Advanced Medicine, Lake Success
University of Rochester, Rochester
Allegheny General Hospital, Pittsburgh
American Oncology Partners of Maryland, PA, Bethesda
Virginia Cancer Specialists - Fairfax, Fairfax
Messino Cancer Centers, Asheville
Emory Saint Joseph's Hospital, Atlanta
AdventHealth Orlando, Orlando
AdventHealth Celebration, Celebration
Gabrail Cancer Research Center, Canton
Siteman Cancer Center - Washington University Medical Campus, St Louis
Highlands Oncology Group, PA - North Hills, Springdale
California Cancer Associates for Research and Excellence (CCARE)-Fresno, Fresno
UCSF Medical Center at Mission Bay, San Francisco
Yale Cancer Center, New Haven
Merck Sharp & Dohme LLC
INDUSTRY
Vaccinex Inc.
INDUSTRY